BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...Sage Therapeutics Inc. (NASDAQ:SAGE), where she was VP, global commercial strategy. Cancer and antivirals company Chimerix Inc....
...senior director of patient services. Robin Sawka, BioCentury Staff BridgeBio Pharma Inc. FibroGen Inc. Storm Therapeutics Ltd. Athenex Inc. Seres Therapeutics Inc. Chimerix Inc. Catalyst...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...the Phase I compound CMX521 from Cocrystal Pharma Inc. (NASDAQ:COCP) and preclinical compound CC-1845 from Chimerix Inc....
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...Asklepios BioPharmaceutical Inc. hired Tim Trost as CFO, a new position. He was CFO of Chimerix Inc....
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...Drug List (see “Innovent’s Tyvyt Edges Out PD-1s” ). Chimerix plans rolling NDA for brincidofovir Chimerix Inc....
...received clearance from FDA to begin a rolling NDA submission for brincidofovir to treat smallpox. Chimerix...
...Programmed cell death 1 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Avadel Pharmaceuticals plc Innovent Biologics Inc. Eli Lilly and Co. Chimerix Inc. Supernus...
BioCentury | May 9, 2019
Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

...Chimerix abandons brincidofovir trials Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue...
...patient recruitment, five years after access to the therapy sparked a firestorm over compassionate use. Chimerix...
BioCentury | Apr 9, 2019
Company News

Management tracks: Cyclerion, Alkermes, Alder

...was executive director, global brand leader, antibiotics at Merck & Co. Inc. (NYSE:MRK). Antiviral company Chimerix Inc....
...Gang as CEO. He was an independent non-executive member of the board. BioCentury Staff Alder BioPharmaceuticals Inc. Alkermes plc Chimerix Inc. Cyclerion...
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

...Robert Friesen as CSO. Friesen was CSO at Ablynx N.V., which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired. Chimerix Inc....
BioCentury | Dec 15, 2018
Regulation

FDA to facilitate access to unapproved drugs

...Few companies publicly disclose statistics on expanded access requests. In 2014, when the decision by Chimerix Inc....
...actually use the information to expand the label,” Gottlieb told BioCentury. Companies and Institutions Mentioned Chimerix Inc....
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

...has exclusive, worldwide rights to the product from Chimerix (see BioCentury, Dec. 22, 2014 ). Chimerix Inc....
...infection Endpoint: Safety and antiviral activity; pharmacokinetics Status: Interim Phase IIa data Milestone: NA Jaime De Leon TXL Chimerix Inc. ContraVir...
BioCentury | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

...in the U.S., EU and Japan to prevent CMV infection in at-risk populations. In 2015, Chimerix Inc....
Items per page:
1 - 10 of 176
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...Sage Therapeutics Inc. (NASDAQ:SAGE), where she was VP, global commercial strategy. Cancer and antivirals company Chimerix Inc....
...senior director of patient services. Robin Sawka, BioCentury Staff BridgeBio Pharma Inc. FibroGen Inc. Storm Therapeutics Ltd. Athenex Inc. Seres Therapeutics Inc. Chimerix Inc. Catalyst...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...the Phase I compound CMX521 from Cocrystal Pharma Inc. (NASDAQ:COCP) and preclinical compound CC-1845 from Chimerix Inc....
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...Asklepios BioPharmaceutical Inc. hired Tim Trost as CFO, a new position. He was CFO of Chimerix Inc....
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...Drug List (see “Innovent’s Tyvyt Edges Out PD-1s” ). Chimerix plans rolling NDA for brincidofovir Chimerix Inc....
...received clearance from FDA to begin a rolling NDA submission for brincidofovir to treat smallpox. Chimerix...
...Programmed cell death 1 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Avadel Pharmaceuticals plc Innovent Biologics Inc. Eli Lilly and Co. Chimerix Inc. Supernus...
BioCentury | May 9, 2019
Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

...Chimerix abandons brincidofovir trials Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue...
...patient recruitment, five years after access to the therapy sparked a firestorm over compassionate use. Chimerix...
BioCentury | Apr 9, 2019
Company News

Management tracks: Cyclerion, Alkermes, Alder

...was executive director, global brand leader, antibiotics at Merck & Co. Inc. (NYSE:MRK). Antiviral company Chimerix Inc....
...Gang as CEO. He was an independent non-executive member of the board. BioCentury Staff Alder BioPharmaceuticals Inc. Alkermes plc Chimerix Inc. Cyclerion...
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

...Robert Friesen as CSO. Friesen was CSO at Ablynx N.V., which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired. Chimerix Inc....
BioCentury | Dec 15, 2018
Regulation

FDA to facilitate access to unapproved drugs

...Few companies publicly disclose statistics on expanded access requests. In 2014, when the decision by Chimerix Inc....
...actually use the information to expand the label,” Gottlieb told BioCentury. Companies and Institutions Mentioned Chimerix Inc....
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

...has exclusive, worldwide rights to the product from Chimerix (see BioCentury, Dec. 22, 2014 ). Chimerix Inc....
...infection Endpoint: Safety and antiviral activity; pharmacokinetics Status: Interim Phase IIa data Milestone: NA Jaime De Leon TXL Chimerix Inc. ContraVir...
BioCentury | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

...in the U.S., EU and Japan to prevent CMV infection in at-risk populations. In 2015, Chimerix Inc....
Items per page:
1 - 10 of 176